Cutaneous lupus erythematosus

SLE Market Size Worth $3.08 Billion by 2025 | CAGR 7.0%: Grand View Research, Inc.

Retrieved on: 
Wednesday, September 12, 2018
Medicine, Immunology, Anatomy, Autoimmune diseases, Kidney diseases, Cutaneous lupus erythematosus, Rheumatology, Lupus nephritis, Systemic lupus erythematosus, Lupus erythematosus, Anti-SSA/Ro autoantibodies, Nephritis

The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.

Key Points: 
  • The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.
  • This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.
  • By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.
  • Grand View Research has segmented the global systemic lupus erythematosus market by drug class, route of administration, and region:
    Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million, 2014 - 2025)

Lupus: A hidden financial burden on health care

Retrieved on: 
Wednesday, August 8, 2018
Health, Medicine, Medical terminology, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Health care, Medical diagnosis

But findings suggest that, over the two years before diagnosis, these patients mainly young women amass more than $2.7 million in extra health care costs.

Key Points: 
  • But findings suggest that, over the two years before diagnosis, these patients mainly young women amass more than $2.7 million in extra health care costs.
  • "These numbers reveal that early detection is key to reducing the burden that lupus places on health care systems around the world," Avia-Zubieta said.
  • Yet, few studies have been conducted on the impact of lupus on the health care system before diagnosis.
  • "This research has given us a better understanding of how serious health events before a lupus diagnosis impact the health care system," Avia-Zubieta said.

Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples

Retrieved on: 
Wednesday, July 25, 2018
Immunology, Medicine, Anatomy, Autoimmune diseases, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Belimumab, Rheumatology, Anti-SSA/Ro autoantibodies

Rheumatologists describe the ideal Benlysta patient as having failed prior treatments, experiencing active disease, and with little to no renal involvement.

Key Points: 
  • Rheumatologists describe the ideal Benlysta patient as having failed prior treatments, experiencing active disease, and with little to no renal involvement.
  • Although half of respondents indicated clinical trial populations were representative of their SLE patient population, further analysis on the clinical trial inclusion/exclusion criteria for investigational agents suggests otherwise.
  • Patients that were excluded from clinical trials have been treated with an assortment of steroids, immunosuppressants, and biologics across different time points.
  • RealWorld Dynamix: Systemic Lupus Erythematosus US is based on a robust and deep patient chart analysis of ~1,000 patients who have been diagnosed with systemic lupus erythematosus and are either currently treated with Benlysta or considered candidates for systemic treatments.

Scientific and Technology Breakthroughs Show Promise for Lupus and Other Immunologic Diseases

Retrieved on: 
Monday, July 16, 2018
Anatomy, Autoimmune diseases, Immunology, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Medicine, Lupus Foundation of America

Building on decades of work, these scientists have used cutting-edge technology to quickly and efficiently insert beneficial genes at exact locations within human immune cells.

Key Points: 
  • Building on decades of work, these scientists have used cutting-edge technology to quickly and efficiently insert beneficial genes at exact locations within human immune cells.
  • More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Outcome Health And The Lupus Initiative® Work Together To Raise Patient Awareness

Retrieved on: 
Tuesday, May 15, 2018
Health, Anatomy, Medicine, Autoimmune diseases, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Lupus, Rheumatology, Quality of life, Health equity, Lupus Canada

CHICAGO, May 15, 2018 /PRNewswire/ --Outcome Health, a technology company that provides health education at the moment of care to improve patient outcomes, today announced the continuation of an initiative to raise awareness of lupus across the country.

Key Points: 
  • CHICAGO, May 15, 2018 /PRNewswire/ --Outcome Health, a technology company that provides health education at the moment of care to improve patient outcomes, today announced the continuation of an initiative to raise awareness of lupus across the country.
  • "ACR's Lupus Initiative designs educational programs that increase awareness about lupus, advance health equity, eliminate health disparities, and improve the quality of life for people living with lupus," said Sheryl McCalla, ACR Senior Director of Collaborative Initiatives.
  • "By working with Outcome Health, we reach people with lupus and people experiencing lupus symptoms nationwide during the critical moments when they're with their healthcare provider."
  • In recognition of Lupus Awareness month in May, Outcome Health and TLI will focus on deploying resources to educate patients and providers about the signs and symptoms of lupus across Outcome Health's nationwide rheumatology network.

International Survey Shows Low Global Understanding about Lupus

Retrieved on: 
Wednesday, May 9, 2018
Anatomy, Immunology, Autoimmune diseases, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Lupus, Medicine, Lupus Foundation of America, The Hibbs Lupus Trust

WASHINGTON, May 9, 2018 /PRNewswire-USNewswire/ --A large-scale international survey reveals that low awareness of lupus results in public misconceptions about the disease.The lack of understanding contributes to the stigmatization of people with lupus, often leaving them feeling isolated from family and friends.

Key Points: 
  • WASHINGTON, May 9, 2018 /PRNewswire-USNewswire/ --A large-scale international survey reveals that low awareness of lupus results in public misconceptions about the disease.The lack of understanding contributes to the stigmatization of people with lupus, often leaving them feeling isolated from family and friends.
  • The full 16-nation survey results are being released on the occasion of World Lupus Day, May 10, by the World Lupus Federation (WLF) at worldlupusday.org.
  • The survey also revealed social stigmas toward people living with lupus because of a misconception that lupus is contagious.
  • Despite low public knowledge about lupus, the survey found broad support for efforts to raise awareness among survey participants.

Lupus Research Alliance and Lupus Therapeutics Collaborate with Bristol-Myers Squibb on a New Lupus Trial

Retrieved on: 
Thursday, April 26, 2018
Anatomy, Medicine, Immunology, Autoimmune diseases, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Lupus, Alliance for Lupus Research, Lupus Foundation of America

Recognizing the limited treatments for lupus, LuCIN was organized, managed and is funded by Lupus Therapeutics as an affiliate of the Lupus Research Alliance to address the slow pace of development of new lupus therapies.

Key Points: 
  • Recognizing the limited treatments for lupus, LuCIN was organized, managed and is funded by Lupus Therapeutics as an affiliate of the Lupus Research Alliance to address the slow pace of development of new lupus therapies.
  • "There remains a desperate need for effective treatments for lupus without the serious side effects common with existing options," noted Albert Roy, Executive Director, Lupus Therapeutics.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by financing the most innovative lupus research in the world.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Washington, DC Shows its Power and Walks to End Lupus Now® May 12th on the National Mall

Retrieved on: 
Tuesday, April 24, 2018
Anatomy, Lupus Foundation of America, Immunology, Autoimmune diseases, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Medicine, The Hibbs Lupus Trust

WASHINGTON, April 24, 2018 /PRNewswire-USNewswire/ -- On Saturday May 12th, thousands of people in Washington, DC will experience the Walk to End Lupus Now DC event on the National Mall.

Key Points: 
  • WASHINGTON, April 24, 2018 /PRNewswire-USNewswire/ -- On Saturday May 12th, thousands of people in Washington, DC will experience the Walk to End Lupus Now DC event on the National Mall.
  • The world's largest lupus walk program, the Lupus Foundation of America's Walk to End Lupus Now brings communities together to raise money for lupus research, increase awareness of lupus and rally public support for those who suffer from its brutal and potentially life-threatening impact.
  • This year, the Foundation's walks will celebrate the theme Be Powerful, as each walk recognizes the strength of those affected by lupus.
  • The family-friendly DC walk will include entertainment, appearances from the Washington Nationals Racing Presidents, and more.

Allegheny Health Network’s Dr. Susan Manzi Among Leading Experts to Propose New Solutions to Advancing the Treatment of Lupus Through Clinical Trials

Retrieved on: 
Wednesday, March 28, 2018
Health, Medicine, Autoimmune diseases, Clinical research, Cutaneous lupus erythematosus, RTT, Systemic lupus erythematosus, Allegheny Health Network, Clinical trial, Lupus

This represents the first time the nation’s lupus research community has come together in providing new research protocols for the FDA’s consideration.

Key Points: 
  • Entitled Lupus Community Panel Proposals for Optimizing Clinical Trials: 2018, the white paper offers recommendations to the U.S. Food and Drug Administration (FDA) for improving clinical trials of new treatments for lupus.
  • This represents the first time the nations lupus research community has come together in providing new research protocols for the FDAs consideration.
  • Merrill, Manzi and Werth re-evaluated data from numerous failed lupus clinical trials that have taken place over the last several decades.
  • About the Allegheny Health Network
    Allegheny Health Network (AHN.org), a Highmark Health company, is an integrated healthcare delivery system serving the greater Western Pennsylvania region.